FEMY News and Press, Femasys Inc. From 04/18/23

2023-04-18 09:30:06 ET Health Canada approved Femasys' ( NASDAQ: FEMY ) FemaSeed, a product for localized directional insemination for infertility The company said FemaSeed is the first-ever infertility solution aimed to deliver sperm directly to the fallopian tube w...

- FemaSeed ® is the first-ever, first-line approach designed to deliver sperm directly where contraception occurs - ATLANTA, April 18, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products...

2023-03-30 09:40:51 ET Femasys press release ( NASDAQ: FEMY ): FY GAAP EPS of -$0.96. Revenue of $1.21M (+2.5% Y/Y). Research and Development expenses were $5,813,755 for the year ended December 31, 2022 compared to $4,084,304 in the same period of 2021. Gene...

- 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which underscored the importance of potential reproductive health options like Femasys’ FemBloc ® for permanent birth control and FemaSeed ® for infertility - The...

ATLANTA, March 09, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, announced today that Kathy Lee-Sepsick,...

-- FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast -- -- FemCath is used in conjunction with FemVue as a baseline diagnostic test for infertility -- ATLANTA, Dec. 19, 2022 (GLOBE NEWS...

--FemCerv ® , the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented at the AAGL conference attended by over 2,000 leading gynecologic specialists-- ATLANTA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Femasys ...

ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that it has comple...

ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee...

--FemaSeed ® de novo trial enrollment accelerates with strategic trial design update to focus on male factor infertility-- -- Company remains on track to file an Investigational Device Exemption (IDE) for a pivotal trial to support a Pre-Market Authorization...